CION Ameerpet
If your Hodgkin lymphoma has returned, or never fully responded, it does not mean the end of the road. There is a clear, guideline-based pathway of salvage treatment — and Hodgkin lymphoma remains one of the more treatable cancers even after relapse.
Hearing that your Hodgkin lymphoma has come back is frightening — but it is important to know that this is a well-understood situation with a clear, evidence-based pathway of options. Relapsed Hodgkin lymphoma means the disease returned after a period of remission, when treatment had made it undetectable. Many people describe it simply as their Hodgkin came back.
Refractory Hodgkin lymphoma is slightly different: it means the disease did not fully respond to first-line treatment, or grew while on it. People searching for refractory Hodgkin treatment are usually in this group. The distinction matters because refractory disease and early relapse tend to need more intensive treatment, while a later relapse may respond well to further therapy.
Either way, the reassuring reality is that Hodgkin lymphoma remains one of the more treatable cancers even at relapse, and there is an established second-line pathway. This page explains what typically comes next; for the specific drug regimens and full treatment detail, see our Lymphoma Treatment in Hyderabad page, and for the wider picture our Lymphoma hub.
Hodgkin lymphoma is considered one of the most curable cancers — published series commonly report around 80–90% overall survival for the disease as a whole, and even after a relapse a substantial proportion of people achieve durable remission with salvage chemotherapy followed by an autologous stem cell transplant. Figures for relapsed disease are lower than for newly diagnosed disease and vary considerably by individual. (Source: figures consistent with NCCN and ESMO Hodgkin lymphoma guidelines and published outcome series.)
After treatment for Hodgkin lymphoma, most symptoms have ordinary causes and are not a relapse. But some signs should always be reported to your team so they can be checked — usually with a scan.
These are the same "B symptoms" that can appear at first diagnosis. If they return after remission, your team will arrange imaging to check. Speak to a CION haematology specialist if you notice these signs after Hodgkin lymphoma treatment.
A relapse is exactly the moment when a joined-up, guideline-driven plan makes the biggest difference. Here is how CION approaches it.
Before any treatment changes, CION confirms the relapse with a PET-CT scan and, in most cases, a repeat biopsy — arranged directly. This avoids treating on the basis of a scan alone and re-checks markers such as CD30 that guide therapy choices.
Relapsed and refractory cases are reviewed by a multidisciplinary tumour board — haematology, medical oncology and radiation together — so the salvage plan follows NCCN and ESMO guidance, not one person's view.
Second-line chemotherapy, antibody therapy, immunotherapy and radiation are delivered in-house by CION. Where a stem cell transplant is needed, CION coordinates it through accredited partner facilities and manages your care throughout.
If you were treated elsewhere, our lymphoma doctors offer a free written second opinion on your PET-CT and pathology, so you can be confident the recommended next step is the right one.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Your Hodgkin lymphoma has come back, or never fully responded, and you want to understand the salvage and transplant options? CION's lymphoma team is here to guide you.
Before any treatment changes, the team confirms that the disease has genuinely returned and maps exactly where it is. CION delivers this diagnostic pathway directly:
A PET-CT scan shows where the lymphoma is metabolically active and how much disease is present. It is the key imaging test for confirming a relapse, planning salvage treatment, and later checking how well that treatment is working.
In most cases a repeat biopsy of an affected lymph node is taken. This confirms the disease is Hodgkin lymphoma again — not a different lymphoma or a benign cause — and lets the pathologist re-check markers such as CD30, which can guide antibody-based therapy choices. CION coordinates the biopsy and reviews the pathology in-house.
Blood tests, and sometimes a bone-marrow examination, assess the overall disease burden and check that the heart, lungs, kidneys and liver are fit for intensive salvage treatment. This matters because the pathway may include high-dose therapy and transplant. All of this is discussed at CION's multidisciplinary tumour board before the plan is set, in line with NCCN and ESMO guidance.
The right plan depends on when the disease came back, how much is present, how you responded before, and your overall fitness. The main building blocks, in the order they are usually considered, are:
The usual first step is salvage chemotherapy — a different, more intensive combination than was used first-line — to bring the disease back under control. How well the disease responds to salvage treatment (assessed on a repeat PET-CT) is one of the strongest predictors of the outcome and guides what comes next. CION delivers salvage chemotherapy directly. Specific regimen names are covered on the Lymphoma Treatment page.
For many people who respond well to salvage chemotherapy, the next step is high-dose therapy supported by an autologous stem cell transplant — using your own stem cells to help the bone marrow recover after intensive treatment. This offers the best chance of a durable remission for suitable patients. Transplant is coordinated by CION through accredited partner facilities, not performed in-house; CION manages your care before and after.
Newer agents have changed the picture for relapsed Hodgkin lymphoma. An antibody-drug conjugate that targets the CD30 marker on Hodgkin cells, and checkpoint-inhibitor immunotherapy, are increasingly used — before transplant to improve response, after transplant to reduce relapse risk, or on their own for selected patients. CION delivers these systemic therapies directly. We describe therapies by drug class here; the Treatment page covers named regimens.
For a relapse confined to a limited area, precision radiation therapy (IMRT) may be used — sometimes alone for a localised late relapse, or combined with systemic treatment. CION delivers radiation in-house, shaping the beam to the disease while sparing healthy tissue.
For a small number of people whose disease is refractory to several lines of treatment, advanced cellular therapy may be considered. Like transplant, this is coordinated through accredited partner facilities — CION assesses suitability, manages the referral, and looks after your ongoing care.
It is natural to want a number, but the honest answer is that the outlook varies a great deal from person to person. What we can say with confidence is that Hodgkin lymphoma is highly treatable, and that a relapse is not the same as running out of options.
Across published series, Hodgkin lymphoma overall carries a high survival rate — commonly cited at around 80–90% for the disease as a whole. For relapsed disease, a substantial proportion of people go on to achieve a durable remission after salvage chemotherapy and autologous stem cell transplant, and newer antibody and immunotherapy agents have improved outcomes further (per NCCN and ESMO). By comparison, aggressive non-Hodgkin lymphomas such as DLBCL are often cited at around 60–70% survival, which puts Hodgkin lymphoma's favourable profile in context.
These figures are general and vary considerably by individual — depending on when the relapse happened, how much disease is present, and the response to salvage treatment. They are not a prediction for any one person. For more detail see our Hodgkin lymphoma survival & cure rates page.
A relapse is one of the most valuable moments to seek a second opinion, because the plan set now shapes everything that follows. It is especially worth it if:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, with transparent costs explained up front. Request your free second opinion or call 18002028726. You can also read about our lymphoma hospital in Hyderabad and the wider Hodgkin lymphoma picture, including Hodgkin lymphoma symptoms.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if a PET-CT, repeat biopsy or transplant assessment has not yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Relapsed Hodgkin lymphoma means the disease has come back after a period of remission — that is, after treatment had made it undetectable. It is different from refractory Hodgkin lymphoma, which means the disease never fully responded to first-line treatment or progressed during it. People often search for this as "my Hodgkin came back". A relapse is usually confirmed with imaging (a PET-CT scan) and, in most cases, a repeat biopsy to be certain the disease is truly Hodgkin lymphoma again and not something else. The good news is that Hodgkin lymphoma remains one of the more treatable cancers even after relapse, and there is a clear, guideline-based pathway of options. Learn what the disease is on our Hodgkin lymphoma page.
For most people with relapsed or refractory Hodgkin lymphoma, the standard approach per NCCN and ESMO guidelines is second-line (salvage) chemotherapy to bring the disease back under control, followed — if there is a good response — by high-dose therapy and an autologous stem cell transplant. Newer options include antibody-drug conjugates targeting the CD30 marker and immunotherapy (checkpoint inhibitors), which are increasingly used before or after transplant. For a small number of people, radiation therapy to a limited area or, in selected refractory cases, cellular therapy through an accredited partner may be considered. The exact plan depends on how you responded before, where the disease is, and your overall health. We describe specific regimens on the Lymphoma Treatment in Hyderabad page rather than here.
Yes — relapsed Hodgkin lymphoma is often still treatable with the goal of long-term remission, which is why it is treated so actively. Published series report that a substantial proportion of people with relapsed Hodgkin lymphoma achieve durable remission after salvage chemotherapy followed by autologous stem cell transplant, and newer antibody and immunotherapy agents have improved outcomes further. Overall, Hodgkin lymphoma carries a high survival rate — commonly cited at around 80–90% across published series for the disease as a whole — though figures for relapsed disease are lower and vary considerably by individual, depending on when the relapse happened, how much disease is present, and the response to salvage treatment (per NCCN and ESMO). No honest team can promise a cure, but the chance of a lasting remission is real and worth pursuing. See our Hodgkin lymphoma survival & cure rates page for context.
People searching for refractory Hodgkin treatment usually mean disease that did not go into remission with first-line treatment, or that grew while on it. A relapse, by contrast, is disease that returned after a remission. The distinction matters because refractory disease and early relapse (within about a year) tend to be more resistant and are generally treated more intensively — often moving toward salvage chemotherapy and an autologous stem cell transplant, with antibody-drug conjugates or checkpoint immunotherapy added per NCCN and ESMO guidance. Late relapse (well beyond a year) may respond well to further treatment. Whichever category applies, the first step is the same: re-confirm the disease with a PET-CT and a fresh biopsy, then plan salvage treatment through a multidisciplinary tumour board.
When a relapse is suspected — because of new symptoms, a new lump, or a scan finding — the team confirms it before changing treatment. This usually includes a PET-CT scan to map where the disease is active, and in most cases a repeat biopsy of an affected node to confirm it is Hodgkin lymphoma again and to re-check markers such as CD30. Blood tests, and sometimes a bone-marrow examination, help assess overall disease burden and organ function before intensive salvage treatment. At CION, PET-CT, biopsy, bone-marrow examination and pathology review are arranged directly, and every relapsed case is discussed at a multidisciplinary tumour board so that the salvage plan is agreed by haematology, medical oncology and radiation experts together.
Not always, but for many people with relapsed or refractory Hodgkin lymphoma an autologous stem cell transplant (using your own stem cells) is a key part of the plan, once salvage chemotherapy has brought the disease under good control. The decision depends on your response to salvage treatment, your age and fitness, and how the disease behaved before. Some people with limited late relapses may be managed with further chemotherapy, antibody therapy or radiation without transplant. Importantly, stem cell transplant and any cellular therapy are coordinated by CION through accredited partner transplant facilities — they are not performed in-house. CION delivers the salvage chemotherapy, immunotherapy, radiation, and all the diagnostic and follow-up care directly, and manages the referral and coordination for transplant.
After treatment for relapsed Hodgkin lymphoma, structured follow-up is important — both to catch any further relapse early and to manage the long-term effects of intensive treatment. This typically involves regular clinical review, imaging as advised, and blood tests, with the frequency easing over time if you stay in remission. Survivorship care also looks at heart and lung health, thyroid function, fertility, and the small long-term risk of second cancers, since these can follow intensive chemotherapy and radiation. CION provides this survivorship and monitoring care directly and coordinates any specialist input needed. If you have finished treatment elsewhere and want a structured survivorship plan or a second opinion on next steps, you can book a free consultation with our team.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.